Morgan Stanley lowered the firm’s price target on Baxter (BAX) to $27 from $28 and keeps an Underweight rating on the shares. The firm continues to like the MedTech industry setup into Q2 on relative stability in procedure volumes and hospital capital expenditures across the space, the analyst tells investors in a research note.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BAX:
- Baxter price target lowered to $32 from $34 at Citi
- Baxter appoints Andrew Hider as CEO
- Baxter International Appoints Andrew Hider as New CEO
- Baxter International Amends Credit and Loan Agreements
- Baxter International Poised for Growth: Buy Rating Affirmed Amid Strategic Initiatives and Promising Outlook